title: Regulation of cGMP synthesis in cultured podocytes by vasoactive hormones.
abstract: The podocytes are highly differentiated cells playing a key role in glomerular filtration. Vasoactive factors including angiotensin II (Ang II) and cyclic guanosine 5' monophosphate (cGMP) are synthesized by these cells upon stimulation as well as in the basal state. In this study we have tested whether angiotensin II affects the total synthesis of cGMP in primary culture of rat podocytes. The cells were stimulated with atrial natriuretic peptide (ANP) and/or a nitric oxide (NO) donor, S-nitroso-N-acetyl penicillamine (SNAP), in the absence or presence of Ang II. The cGMP synthesis was determined by radioimmunoassay (RIA). ANP or SNAP alone increased the cGMP synthesis in podocytes although the effects were not additive unless Ang II was present in the medium. Ang II suppressed the ANP-dependent cGMP synthesis whereas SNAP-dependent cGMP production remained unaffected. These effects were prevented by a non-specific antagonist of Ang II receptors (AT), saralasin. Adversely, PD123319, a specific inhibitor of AT2 receptors, augmented inhibition of ANP-dependent and enhanced the NO-dependent cGMP production. Probenecid, an inhibitor of cGMP extrusion from the cells, suppressed the cGMP generation by both ANP and SNAP. We conclude that cGMP synthesis in cultured podocytes is modulated by angiotensin II and that two adversely acting receptors, AT1 and AT2 are involved in this effect. Additionally, production of cGMP might be intrinsically inhibited by cGMP accumulating inside the cells.
authors.affiliation: Department of Immunopathology, Medical University of Gdansk, Gdansk, Poland. blew@amg.gda.pl
authors.forename: B
authors.initials: B
authors.lastname: Lewko
authors.forename: M
authors.initials: M
authors.lastname: Gołos
authors.forename: E
authors.initials: E
authors.lastname: Latawiec
authors.forename: S
authors.initials: S
authors.lastname: Angielski
authors.forename: J
authors.initials: J
authors.lastname: Stepinski
mesh_terms: D000804:Angiotensin II / Q000494:pharmacology*; D000818:Animals; D009320:Atrial Natriuretic Factor / Q000494:pharmacology*; D002478:Cells, Cultured; D006152:Cyclic GMP / Q000096:biosynthesis*; D007093:Imidazoles / Q000494:pharmacology; D020030:Nitric Oxide Donors / Q000494:pharmacology*; D050199:Podocytes / Q000187:drug effects* / Q000378:metabolism; D011725:Pyridines / Q000494:pharmacology; D011863:Radioimmunoassay; D051381:Rats; D044140:Receptor, Angiotensin, Type 1 / Q000378:metabolism; D044139:Receptor, Angiotensin, Type 2 / Q000378:metabolism; D026423:S-Nitroso-N-Acetylpenicillamine / Q000494:pharmacology*; D012504:Saralasin / Q000494:pharmacology
chemical_list: D007093:Imidazoles; D020030:Nitric Oxide Donors; D011725:Pyridines; D044140:Receptor, Angiotensin, Type 1; D044139:Receptor, Angiotensin, Type 2; D000804:Angiotensin II; C073402:PD 123319; D026423:S-Nitroso-N-Acetylpenicillamine; D009320:Atrial Natriuretic Factor; D012504:Saralasin; D006152:Cyclic GMP